File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients

TitleTransition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
Authors
KeywordsHepatocellular carcinoma
Epidemiology
Asia pacific
Hepatitis B virus
Natural history
Issue Date2021
PublisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072
Citation
Hepatology International, 2021, v. 15 n. 1, p. 71-81 How to Cite?
AbstractBackground: Increasing hepatitis-related mortality has reignited interest to fulfill the World Health Organization’s goal of viral hepatitis elimination by 2030. However, economic barriers have enabled only 28% of countries to implement countermeasures. Given the high disease burden among Asians, we aimed to present age, sex, disease activity and treatment-specific annual progression rates among Asian chronic hepatitis B (CHB) patients to inform health economic modeling efforts and cost-effective public health interventions. Methods: We analyzed 18,056 CHB patients from 36 centers across the U.S. and seven countries/regions of Asia Pacific (9530 treated; 8526 untreated). We used Kaplan–Meier methods to estimate annual incidence of cirrhosis and hepatocellular carcinoma (HCC). Active disease was defined by meeting the APASL treatment guideline criteria. Results: Over a median follow-up of 8.55 years, there were 1178 incidences of cirrhosis and 1212 incidences of HCC (297 without cirrhosis, 915 with cirrhosis). Among the 8526 untreated patients (7977 inactive, 549 active), the annual cirrhosis and HCC incidence ranged from 0.26% to 1.30% and 0.04% to 3.80% in inactive patients, and 0.55 to 4.05% and 0.19 to 6.03% in active patients, respectively. Of the 9530 treated patients, the annual HCC rates ranged 0.03–1.57% among noncirrhotic males and 2.57–6.93% among cirrhotic males, with lower rates for females. Generally, transition rates increased with age, male sex, the presence of fibrosis/cirrhosis, and active disease and/or antiviral treatment. Conclusion: Using data from a large and diverse real-world cohort of Asian CHB patients, the study provided detailed annual transition rates to inform practice, research and public health planning.
Persistent Identifierhttp://hdl.handle.net/10722/305843
ISSN
2020 Impact Factor: 6.047
2020 SCImago Journal Rankings: 1.304

 

DC FieldValueLanguage
dc.contributor.authorLiu, M-
dc.contributor.authorTseng, TC-
dc.contributor.authorJun, DW-
dc.contributor.authorYeh, ML-
dc.contributor.authorTrinh, H-
dc.contributor.authorWong, GLH-
dc.contributor.authorChen, CH-
dc.contributor.authorPeng, CY-
dc.contributor.authorKim, SE-
dc.contributor.authorOh, H-
dc.contributor.authorKwak, MS-
dc.contributor.authorCheung, M-
dc.contributor.authorToyoda, H-
dc.contributor.authorHsu, YC-
dc.contributor.authorJeong, JY-
dc.contributor.authorYoon, EL-
dc.contributor.authorUngtrakul, T-
dc.contributor.authorZhang, J-
dc.contributor.authorXie, Q-
dc.contributor.authorAhn, SB-
dc.contributor.authorEnomoto, M-
dc.contributor.authorShim, JJ-
dc.contributor.authorCunningham, C-
dc.contributor.authorJeong, SW-
dc.contributor.authorCho, YK-
dc.contributor.authorOgawa, E-
dc.contributor.authorHuang, R-
dc.contributor.authorLee, DH-
dc.contributor.authorTakahashi, H-
dc.contributor.authorTsai, PC-
dc.contributor.authorHuang, CF-
dc.contributor.authorDai, CY-
dc.contributor.authorTseng, CH-
dc.contributor.authorYasuda, S-
dc.contributor.authorKozuka, R-
dc.contributor.authorLi, J-
dc.contributor.authorWong, C-
dc.contributor.authorWong, CC-
dc.contributor.authorZhao, C-
dc.contributor.authorHoang, J-
dc.contributor.authorEguchi, Y-
dc.contributor.authorWu, C-
dc.contributor.authorTanaka, Y-
dc.contributor.authorGane, E-
dc.contributor.authorTanwandee, T-
dc.contributor.authorCheung, R-
dc.contributor.authorYuen, MF-
dc.contributor.authorLee, HS-
dc.contributor.authorYu, ML-
dc.contributor.authorKao, JH-
dc.contributor.authorYang, HI-
dc.contributor.authorNguyen, MH-
dc.date.accessioned2021-10-20T10:15:07Z-
dc.date.available2021-10-20T10:15:07Z-
dc.date.issued2021-
dc.identifier.citationHepatology International, 2021, v. 15 n. 1, p. 71-81-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/305843-
dc.description.abstractBackground: Increasing hepatitis-related mortality has reignited interest to fulfill the World Health Organization’s goal of viral hepatitis elimination by 2030. However, economic barriers have enabled only 28% of countries to implement countermeasures. Given the high disease burden among Asians, we aimed to present age, sex, disease activity and treatment-specific annual progression rates among Asian chronic hepatitis B (CHB) patients to inform health economic modeling efforts and cost-effective public health interventions. Methods: We analyzed 18,056 CHB patients from 36 centers across the U.S. and seven countries/regions of Asia Pacific (9530 treated; 8526 untreated). We used Kaplan–Meier methods to estimate annual incidence of cirrhosis and hepatocellular carcinoma (HCC). Active disease was defined by meeting the APASL treatment guideline criteria. Results: Over a median follow-up of 8.55 years, there were 1178 incidences of cirrhosis and 1212 incidences of HCC (297 without cirrhosis, 915 with cirrhosis). Among the 8526 untreated patients (7977 inactive, 549 active), the annual cirrhosis and HCC incidence ranged from 0.26% to 1.30% and 0.04% to 3.80% in inactive patients, and 0.55 to 4.05% and 0.19 to 6.03% in active patients, respectively. Of the 9530 treated patients, the annual HCC rates ranged 0.03–1.57% among noncirrhotic males and 2.57–6.93% among cirrhotic males, with lower rates for females. Generally, transition rates increased with age, male sex, the presence of fibrosis/cirrhosis, and active disease and/or antiviral treatment. Conclusion: Using data from a large and diverse real-world cohort of Asian CHB patients, the study provided detailed annual transition rates to inform practice, research and public health planning.-
dc.languageeng-
dc.publisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072-
dc.relation.ispartofHepatology International-
dc.rightsAccepted Manuscript (AAM) This is a post-peer-review, pre-copyedit version of an article published in [insert journal title]. The final authenticated version is available online at: https://doi.org/[insert DOI]-
dc.subjectHepatocellular carcinoma-
dc.subjectEpidemiology-
dc.subjectAsia pacific-
dc.subjectHepatitis B virus-
dc.subjectNatural history-
dc.titleTransition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients-
dc.typeArticle-
dc.identifier.emailCheung, M: cks634@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityCheung, M=rp02532-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12072-020-10113-2-
dc.identifier.pmid33394321-
dc.identifier.scopuseid_2-s2.0-85098964636-
dc.identifier.hkuros326990-
dc.identifier.volume15-
dc.identifier.issue1-
dc.identifier.spage71-
dc.identifier.epage81-
dc.publisher.placeIndia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats